These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27013200)

  • 21. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
    Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
    Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of multidrug resistance in gastric cancer cells by E2F-1 downregulation in vitro and in vivo.
    Yan LH; Wang XT; Yang J; Kong FB; Lian C; Wei WY; Luo W; Xie YB; Xiao Q
    J Cell Biochem; 2014 Jan; 115(1):34-41. PubMed ID: 24038122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells.
    Subhash VV; Tan SH; Tan WL; Yeo MS; Xie C; Wong FY; Kiat ZY; Lim R; Yong WP
    BMC Cancer; 2015 Jul; 15():550. PubMed ID: 26209226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNAi knockdown of the Akt1 gene increases the chemosensitivity of gastric cancer cells to cisplatin both in vitro and in vivo.
    Zhou W; Fu XQ; Liu J; Yu HG
    Regul Pept; 2012 Jun; 176(1-3):13-21. PubMed ID: 22387880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells.
    Wang Z; Wang Q; Xu G; Meng N; Huang X; Jiang Z; Chen C; Zhang Y; Chen J; Li A; Li N; Zou X; Zhou J; Ding Q; Wang S
    RNA Biol; 2020 Nov; 17(11):1576-1589. PubMed ID: 31885317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Reversion of multidrug resistance of human gastric cancer SGC7901/DDP cells by E2F-1 gene silencing].
    Lian C; Yang J; Wang X; Xie Y; Xiao Q
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):171-6. PubMed ID: 24785275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HZ08 reverse the aneuploidy-induced cisplatin-resistance in Gastric cancer by modulating the p53 pathway.
    Tang X; Hu G; Xu C; Ouyang K; Fang W; Huang W; Zhang J; Li F; Wang K; Qin X; Li Y
    Eur J Pharmacol; 2013 Nov; 720(1-3):84-97. PubMed ID: 24183976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer.
    Teng F; Xu Z; Chen J; Zheng G; Zheng G; Lv H; Wang Y; Wang L; Cheng X
    Oncol Rep; 2018 Sep; 40(3):1203-1222. PubMed ID: 29956792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
    PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
    Xie X; Tang B; Zhou J; Gao Q; Zhang P
    Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of FAM3B Promotes Cisplatin Resistance in Gastric Cancer by Inducing Epithelial-Mesenchymal Transition.
    Song C; Duan C
    Med Sci Monit; 2020 May; 26():e921002. PubMed ID: 32442162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells.
    Fang Y; Shen H; Li H; Cao Y; Qin R; Long L; Zhu X; Xie C; Xu W
    Acta Biochim Biophys Sin (Shanghai); 2013 Nov; 45(11):963-72. PubMed ID: 24108762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. USP14 as a novel prognostic marker promotes cisplatin resistance via Akt/ERK signaling pathways in gastric cancer.
    Fu Y; Ma G; Liu G; Li B; Li H; Hao X; Liu L
    Cancer Med; 2018 Nov; 7(11):5577-5588. PubMed ID: 30296012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
    Xu W; Chen Q; Wang Q; Sun Y; Wang S; Li A; Xu S; Røe OD; Wang M; Zhang R; Yang L; Zhou J
    Cell Death Dis; 2014 Dec; 5(12):e1551. PubMed ID: 25476899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN.
    Yang SM; Huang C; Li XF; Yu MZ; He Y; Li J
    Toxicology; 2013 Apr; 306():162-8. PubMed ID: 23466500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression.
    Gou WF; Shen DF; Yang XF; Zhao S; Liu YP; Sun HZ; Su RJ; Luo JS; Zheng HC
    Oncotarget; 2015 Aug; 6(23):19552-79. PubMed ID: 25980581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo.
    Zhang J; Zhu JS; Zhou Z; Chen WX; Chen NW
    Oncol Rep; 2012 May; 27(5):1511-9. PubMed ID: 22246223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.
    Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
    Med Oncol; 2015 Apr; 32(4):133. PubMed ID: 25796504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.